arrow
A

Andrew W. Stamford

merck & company
H指数:36
被引数:3,947

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Recruitment of FBXO22 for targeted degradation of NSD2

招募FBXO22靶向降解NSD2

2024-07-047
PRE
Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia
2022-09-0234
OAAI
Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
2021-02-2527
OA
Whole Cell Active Inhibitors of Mycobacterial Lipoamide Dehydrogenase Afford Selectivity over the Human Enzyme through Tight Binding Interactions
2021-02-023
OAAI
Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression
2019-05-21180
OAAI
Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety
2018-11-0210
PREAI
Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors
2017-11-2137
OAAI
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity
2017-03-16113
PREAI
Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease
2016-11-18133
OAAI
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients
2016-11-02354
PREAI
Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates
2016-03-2239
PREAI
Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes
2015-07-1314
OAAI
The Discovery of N-((2H-Tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): A Potent and Selective Glucagon Receptor Antagonist
2014-02-2617
PREAI